Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
High rates of modifiable cancer risk factors present in Western HIV-positive patients

The prevalence of potentially modifiable risk factors for some cancers is “extraordinarily high” among people with HIV, according to results of a meta-analysis published in

Published
18 January 2016
By
Michael Carter
J&J signs deal with Chinese company for hepatitis B drug

The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November. Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood. J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.

Published
08 January 2016
From
Reuters
I am surviving only on 25 per cent of my liver today: Amitabh Bachchan

Bollywood megastar Amitabh Bachchan made a startling revelation about surviving only on 25 per cent of his liver today having lost the rest 75 percent to the deadly Hepatitis B virus. Speaking at the launch of media campaign for on Hepatitis, Amitabh Bachchan recollected how he contracted the disease.

Published
24 November 2015
From
The Indian Express
Tenofovir during pregnancy reduces risk of mother-to-child hepatitis B virus transmission

Women with chronic hepatitis B and high viral load who were treated with tenofovir (Viread) during pregnancy were significantly less likely to transmit hepatitis B virus (HBV) to

Published
20 November 2015
By
Liz Highleyman
REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection

The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load

Published
16 November 2015
By
Liz Highleyman
HIV Drugs Provide Added Benefit of Protecting Against Hepatitis B Virus

A cohort study involving 2,400 men who have sex with men has shown that men with HIV who were treated effectively with HIV therapy — defined as no detectable HIV virus in the blood — were the least likely (80 percent less likely) to get infected with HBV over a median follow-up of approximately 9.5 years, compared with men with HIV who were not on HIV therapy or men who had detectable HIV virus while on HIV therapy.

Published
13 October 2015
From
Johns Hopkins Medicine
ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®

The Company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF. ContraVir plans to file an investigational new drug (IND) application for CMX157 to treat HBV before year-end 2015. CMX157 benefits from earlier human studies in volunteers under an IND for HIV. ContraVir is focused on a quick evaluation of CMX157 in a Phase 2 clinical study in patients with hepatitis B which it plans to begin in 2016.

Published
06 October 2015
From
Contravir press release
Cost of comprehensive global viral hepatitis prevention and treatment effort might peak at $11 billion in 2025

Reaching the World Health Organization’s (WHO) proposed targets for viral hepatitis control by 2030 could require global funding of $11 billion per year by 2025, Stefan Wiktor

Published
15 September 2015
By
Keith Alcorn
World Health Organization calls for ambitious global targets for viral hepatitis control

The World Health Organization (WHO) is calling for ambitious new global targets for diagnosis, treatment and cure of viral hepatitis, signalling a major increase in momentum towards

Published
03 September 2015
By
Keith Alcorn
After Curing Hepatitis C, Gilead Works to Vanquish More Viruses

Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.

Published
19 August 2015
From
Bloomberg

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.